secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K/A
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001828185-24-000046
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Q1 net loss $15.5M; VTP-200 misses stat sig; VTP-1000 IND cleared; CMO appointed
--------------------------------------------------------------------------------

- Net loss was $15.5M ($0.40/share), compared to $18.2M ($0.48) in Q1 2023; revenue nil.
- Cash position $130.0M as of Mar 31, 2024; cash runway into Q4 2025.
- VTP-200 Phase 1b/2 APOLLO met safety but no stat sig improvement in hrHPV or lesion clearance vs placebo.
- VTP-1000 IND cleared for Phase 1 celiac trial; first patient dosing expected Q3 2024.
- Appointed Dr. Leon Hooftman as CMO effective June 3, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000046/0001828185-24-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000046/brns-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001828185-24-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer